Ctsa K12 program at harvard medical school

Active Project Grant Awarded Last action

Award ID
K12TR004381
Recipient
Awarding agency
Obligated
$16,198,000

Award facts

Completion date 70% complete
Place of performance
Mission Hill, MA 02120, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The goal of the harvard catalyst K12 program is to create an environment for early-stage clinical and translational (CT) investigators that facilitates their career development and encourages paradigm-shifting, diversity-focused interdisciplinary collaboration and team-based research approaches to advance CT science. Since its founding in 2008, the harvard catalyst KL2 program has served as the cornerstone across harvard medical school (HMS) and its affiliated academic medical centers for training our most outstanding early-stage CT investigators. Given the demonstrated success of the KL2 program since 2008, the new K12 program will build on the KL2 program's strengths. The new K12 program will specifically seek to help train and develop the future leaders of CT science by leveraging the harvard catalyst cores and integrating the scholars into the broader CT infrastructure at harvard catalyst and the ctsa consortium. In addition, through dedicated funding from the HMS-affiliated amcs, the K12 program will continue to be paired with the catalyst medical research investigator (CMERIT) program to further enrich the K12 learning environment. Moreover, through the continued growth and expansion of the clinical and translational research academy, a supporting infrastructural element of harvard catalyst, the K12 will create a community for CT investigators and enhance the transition to independence for all K awardees across HMS. Finally, the K12 program will work closely with the harvard catalyst cores and other NIH-funded programs at HMS to enhance the research capability, competency and performance of all K12 awardees with a new focus on translational science. The overarching objective of the program is to ensure and nurture the sustainable careers of early-stage CT investigators and ultimately advance translational science. The K12 program will offer sustained protected time for scholars to advance their CT research, overseen by a primary mentor and CO-mentor and now further enhanced by a dedicated mentorship committee, including a separate career mentor to provide outside input on broader career goals. Training will include the use of new courses and programs, including our monthly translate together curriculum, that covers the broad translational spectrum and focuses on developing innovative solutions that improve human health. IT will also include the development of individualized career development programs, leadership training, visibility through participation in the national ctsa visiting scholar program, and mentor/mentee training, to ensure the success of each scholar as a translational scientist as envisioned by ncats. The K12 will also seek to educate scholars on the importance of community engagement for the execution of effective CT research to ensure the highest quality science can be completed. In a related context, building on our earlier success in improving the diversity of the KL2 program, we will continue several diversity and inclusion initiatives both to ensure that we have a vibrant and diverse group of scholars but also to ensure that all scholars are fully educated on diversity as a critical feature of all successful CT research endeavors.

Transactions

Action Obligated Date
Amendment $0
Amendment $1,619,800
Amendment $1,619,800
Amendment $0
Amendment $0
Amendment $1,619,800
Amendment $1,619,800
Amendment Ctsa K12 program at harvard medical school - the goal of the harvard catalyst K12 program is to create an environment for early-stage clinical and translational… $1,619,800
Amendment $1,619,800
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,619,800
Amendment $1,619,800
Amendment $1,619,800
Original award $1,619,800
Show all 18

Subawards

Subrecipient Amount Awarded
The Children's Hospital Corporation The proposed project will develop a precise characterization of the human MOG antibody repertoire in MOGAD at the molecular level, create novel reagents derived… $99,213
The General Hospital Corporation My current project seeks to understand how T cells change their cell surface carbohydrates after repeated exposure to targets leading to a phenomenon known as… $265,788
Brigham & Womens Hospital Inc. Obesity is projected to impact 4 billion people by 2035. High-risk obesity with metabolic syndrome components (metabolically unhealthy obesity) contributes to… $212,814
Hebrew Rehabilitation Center I am a biomedical engineer and research scientist who aims to leverage technological advances to detect early signs of longitudinal fall risk changes in older… $51,973
Hebrew Rehabilitation Center $161,587
Beth Israel Deaconess Medical Center, Inc. Tuberculosis (TB) is a leading cause of death and disability from infectious disease worldwide. The Bacillus Calmette–Guérin (BCG) vaccine is given at… $350,562
The General Hospital Corporation Kemar Brown Uncovering gene differences in the human heart based on continental ancestry A critical trend has now emerged highlighting an increase in heart… $366,336
Brigham & Womens Hospital Inc. Understanding the effect of a new Medicare dental benefit on the oral health workforce This project seeks to address the critical gap in oral healthcare… $141,625
Dana-Farber Cancer Institute, Inc. Development of rational combination therapies for NUT carcinoma This 2-year grant will provide necessary salary support for Jia Luo to investigate the questions… $400,491
Brigham & Womens Hospital Inc. Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and associated with 5-fold increase in the risk for cardioembolic… $342,664
The Children's Hospital Corporation Integrating glycosylation into characterization of immune function in patients with Evans syndrome. I will assess T and B cell glycosylation, a… $400,382
The Children's Hospital Corporation Amblyopia is the most common cause of visual impairment among children in the US. Delayed diagnosis and/or inadequate treatment in early childhood may result in… -$134,499
Dana-Farber Cancer Institute, Inc. Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer deaths in women. Most women present with advanced disease which carries a 5-year survival… $58,860
Beth Israel Deaconess Medical Center, Inc. Emergency department visits are common at the end-of-life. Most patients, however, have not considered their healthcare goals and wishes prior to= coming to the… $102,503
The General Hospital Corporation Insulin resistance is a blunted signaling response that is associated with the development and progression of nonalcoholic fatty liver disease (NAFLD).… $76,356
The General Hospital Corporation Sepsis is a devastating problem causing about 11 million deaths worldwide annually. Though diagnosed and treated as a single syndrome, it is highly… $67,379
The General Hospital Corporation The mechanisms underlying the efficacy of oncolytic viruses, which preferentially infect and kill cancer cells, remain poorly understood. One possibility is… $52,416
The General Hospital Corporation Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer deaths in women. Most women present with advanced disease which carries a 5-year survival… $52,416
Dana-Farber Cancer Institute, Inc. My long-term goal is to become an independent extramurally funded investigator with expertise in reducing cancer related disparities and improving… $198,409
The General Hospital Corporation Expanded leukemogenic mutations in the blood indicative of clonal hematopoiesis are increasingly being recognized as risk factors for coronary artery disease… $259,524
The Children's Hospital Corporation Amblyopia is the most common cause of visual impairment among children in the US. Delayed diagnosis and/or inadequate treatment in early childhood may result in… $179,332
Brigham & Womens Hospital Inc. Our ultimate goal is to design, implement, and evaluate a cluster randomized controlled trial assessing the accessibility and appropriateness of three different… $256,608
Brigham & Womens Hospital Inc. $105,300
Dana-Farber Cancer Institute, Inc. Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer deaths in women. Most women present with advanced disease which carries a 5-year survival… $10,800
Beth Israel Deaconess Medical Center, Inc. Emergency department visits are common at the end-of-life. Most patients, however, have not considered their healthcare goals and wishes prior to= coming to the… $10,800
The General Hospital Corporation Sepsis is a devastating problem causing about 11 million deaths worldwide annually. Though diagnosed and treated as a single syndrome, it is highly… $10,800
The General Hospital Corporation Expanded leukemogenic mutations in the blood indicative of clonal hematopoiesis are increasingly being recognized as risk factors for coronary artery disease… $106,812
The General Hospital Corporation Insulin resistance is a blunted signaling response that is associated with the development and progression of nonalcoholic fatty liver disease (NAFLD).… $10,800
Dana-Farber Cancer Institute, Inc. My long-term goal is to become an independent extramurally funded investigator with expertise in reducing cancer related disparities and improving… $72,996
The Children's Hospital Corporation Amblyopia is the most common cause of visual impairment among children in the US. Delayed diagnosis and/or inadequate treatment in early childhood may result in… $104,574
The General Hospital Corporation The mechanisms underlying the efficacy of oncolytic viruses, which preferentially infect and kill cancer cells, remain poorly understood. One possibility is… $10,800
Show all 31

Quick answers

Who received award K12TR004381?

K12TR004381 was awarded to President And Fellows Of Harvard College by National Center for Advancing Translational Sciences (National Institutes of Health) on May 15, 2023.

How much is award K12TR004381 worth?

$16,198,000 has been obligated on K12TR004381.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login